Table 2.
Characteristics of studies included in this meta-analysis.
| Study, year | Country | Duration | Sample size | Tumor type | Study design | Treatment | Survival outcome | Cut-off | NOS |
|---|---|---|---|---|---|---|---|---|---|
| Asakura et al., 2022 (23) | Japan | 2000-2019 | 169 | ECC | Retrospective | Surgery | OS | 3 | 6 |
| Cui et al., 2018 (22) | China | 2012-2017 | 73 | HCCA | Retrospective | PTBS+ 125I | OS | 2 | 5 |
| Mito et al., 2023 (21) | Japan | 2006-2020 | 224 | BTC | Retrospective | Surgery | OS, RFS, DSS | 4 | 6 |
| Miyata et al., 2017 (20) | Japan | 2002-2016 | 71 | ICC | Retrospective | Surgery | OS, RFS | 2 | 7 |
| Shimizu et al., 2022 (19) | Japan | 2002-2018 | 91 | AVC | Retrospective | Surgery | OS | 2 | 7 |
| Sun et al., 2021 (18) | China | 2002-2017 | 371 | BTC | Retrospective | Surgery | OS | 2 | 6 |
| Terasaki et al., 2022 (17) | Japan | 2002-2016 | 149 | DCC | Retrospective | Surgery | OS | 3 | 6 |
| Wang et al., 2021 (16) | China | 2010-2019 | 94 | HCCA | Retrospective | Surgery | OS, RFS | 3 | 7 |
| Zheng et al., 2020 (15) | China | 2012-2018 | 167 | ICC | Retrospective | Surgery | OS, RFS | 3 | 7 |
ECC, extrahepatic cholangiocarcinoma; OS, overall survival; HCCA, hilar cholangiocarcinoma; PTBS+ 125I, percutaneous transhepatic biliary stenting combined with 125I seed intracavitary irradiation; BTC, biliary tract cancer; RFS, relapse-free survival/recurrence-free survival; DSS, disease-specific survival; ICC, intrahepatic cholangiocarcinoma; AVC, ampulla of Vater cancer; DCC, distal cholangiocarcinoma.